We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Nuformix Plc | LSE:NFX | London | Ordinary Share | GB00BYW79Y38 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.01 | -5.41% | 0.175 | 0.17 | 0.18 | - | 1,097,760 | 16:35:25 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -859k | -0.0012 | -1.50 | 1.34M |
Date | Subject | Author | Discuss |
---|---|---|---|
09/9/2023 15:38 | I was talking about real volume from real investors, not the blips afforded by P&D merchants. | for fx sake | |
09/9/2023 12:55 | What's interesting here Board members currently employed in the past have struck substantial deals And the fact NO large holders are selling Even lanstead | amaretto1 | |
09/9/2023 12:53 | Volume can change in 24 hrs What u talking about | amaretto1 | |
08/9/2023 21:05 | The question is whether they have obtained further tissue samples for the required testing or not | hollywood6 | |
08/9/2023 20:25 | They continue to underwhelm Peverill.The patent being published is a non event. It could be at least another 18 months before it's granted, if that happens at all.A deal is the only thing that will make a difference and there's no sign of that, judging by the lack of volume | for fx sake | |
08/9/2023 14:06 | Very quiet given the ERS conference starts tomorrow and a new IPF patent was published a few days ago,are the stars aligning at the right time,plus Boston conference in a few weeks with some NFX related work on show. | peverill | |
06/9/2023 07:06 | Don't think we will get anything till Lanstead agreement is finished. | peverill | |
29/8/2023 10:09 | It's very possible,if it works and gets to market,probably many times 10p.A while off yet,but given results so far it's worth a shot to a large pharma at 10p a share. | peverill |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions